ClinicalTrials.Veeva

Menu

Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Boehringer Ingelheim logo

Boehringer Ingelheim

Status

Completed

Conditions

Heart Failure

Treatments

Drug: JARDIANCE®

Study type

Observational

Funder types

Industry

Identifiers

NCT05262764
1245-0286

Details and patient eligibility

About

Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.

Enrollment

1,200 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with chronic heart failure (CHF) failure who are prescribed with JARDIANCE® Tablets in Japan
  • Patients who have never been treated with Empagliflozin (including treatment for type 2 diabetes mellitus (T2DM)) before enrolment

Exclusion criteria

  • None

Trial design

1,200 participants in 1 patient group

Patients with chronic heart failure (CHF)
Treatment:
Drug: JARDIANCE®

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems